FDA gets 2 years to build patient recall alert system for implanted devices

What it does

This bill requires medical device manufacturers to notify patients directly when their implanted or life-sustaining devices are recalled, using a standardized electronic format. The FDA must establish the notification system within 2 years, review manufacturer notifications within 2–3 business days, and maintain a public database of all device recalls. Manufacturers who fail to notify patients or use the required format face penalties under federal law.

Why we flagged it

The bill's core function is to establish mandatory electronic notification of device recalls directly to patients and healthcare providers, coupled with FDA oversight and public transparency. It is a regulatory procedural reform, not a substantive restriction on device approval or market access.

What the text implies

• The 180-day implementation window (after FDA establishes the format) may create a gap during which manufacturers continue using older, slower notification methods, delaying patient awareness of serious recalls.
• The bill does not specify penalties for late or incomplete notifications, only that refusal or failure is prohibited—enforcement discretion may vary by FDA administration.
• Patient notification requirements apply only to Class I/II recalls of Class II/III devices that are implanted, life-sustaining, life-supporting, or used in pediatric populations; non-implanted devices and lower-risk recalls are excluded, potentially leaving some patients uninformed.
• The public database may expose proprietary device identifiers and manufacturer contact information at scale, which could increase targeted litigation or regulatory scrutiny of manufacturers.
• No explicit requirement that manufacturers verify patient contact information is current, so notifications may fail to reach patients who have changed providers or moved.

Who it affects

Patients with implanted or life-sustaining devices gain direct, timely notice of safety risks and corrective actions they can take. The public database increases transparency. Manufacturers face modest compliance costs but no substantive restrictions on device approval or marketing.

Who stands to gain

• medical device manufacturers (modest compliance cost offset by reduced litigation risk from faster p
• healthcare IT vendors (potential contracts to integrate electronic notification systems)
• patient advocacy organizations (increased transparency and data access)

Named in the bill

FDA (Food and Drug Administration), Section 518A, 518B, 518C (Federal Food, Drug, and Cosmetic Act), Section 519 (device user facility reporting), Section 301 (prohibited acts), BMY (Bristol Myers Squibb), GH (Guardant Health), PFE (Pfizer), DVA (DaVita), JNJ (Johnson & Johnson)

Where it stands

1 cosponsor: 1 Democrats.

• Dec 10, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 10, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.